# How a dying cancer cell could become an immune weapon > There's an idea that has been circulating for a few years now in immuno-oncology labs and that has resurfaced with renewed intensity - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Column - Published: 2026-07-06 - Canonical URL: https://mad-max.co/en/article/quand-la-mort-d-une-cellule-cancereuse-devient-une-arme-immunitaire ## Introduction: a discovery that cures nothing but changes the question ### What researchers are actually seeing There's an idea that has been circulating for a few years now in **immuno-oncology** labs and that has resurfaced with renewed intensity this summer: not all **cell deaths** are equal. A **cancer cell** that dies by accident, through plain **necrosis**, disappears almost silently. But a cell that dies through certain controlled scripts, such as **immunogenic apoptosis** or **necroptosis**, sends out distress signals on its way out that wake up the surrounding **immune system**. That distinction, already documented by a substantial body of scientific literature, is what now fuels the measured hope of improving existing treatments against **cancer**. The concept has a technical name, **immunogenic cell death**, often shortened to **ICD** in specialized journals. Reviews published notably in **Nature Reviews Immunology** and in journals such as **BMB Reports** detail how molecules called **DAMPs**, for damage-associated molecular patterns, are released by a dying **tumor cell** and go on to alert **dendritic cells**, the immune system's sentinels tasked with presenting antigens to **T cells**. ### Why this subject deserves plain talk, not embellishment I'm not a **biologist** and I will never pretend to be one. What I can do, though, is read carefully what researchers are documenting and resist the temptation of the miracle shortcut that too often pollutes science writing on **cancer**. This line of research is not a treatment, nor even a completed clinical trial. It's a field of study that could eventually be harnessed to strengthen therapies that already exist, notably **immune checkpoint inhibitors**. What strikes me, digging through this literature, is the methodical caution of the authors themselves. A **2025** review published on **PubMed** notes that clinical integration of these mechanisms remains fragmented, with results sometimes limited to **preclinical models**, in cell culture or in animals, still far from widespread application in humans. *I refuse to write a piece that dangles a miracle turning point against cancer. What I can say honestly is that this line of inquiry deserves attention because it reframes a central question: how dying can also mean attacking.* ## Apoptosis, necroptosis, pyroptosis: a short glossary without needless jargon ### Three ways to die that don't send the same signal **Apoptosis** is the most studied form of cell death, an orderly process that is generally silent on the immune front, except under certain particular conditions where it turns **immunogenic**. **Necroptosis**, by contrast, is a form of programmed cell death that looks more like a controlled explosion: the **cell membrane** ruptures and spills its contents into the surrounding tissue, which alerts nearby immune cells far more effectively. **Pyroptosis**, a third pathway, is tied to an even sharper **inflammatory response**. Work published in journals such as **ACS Biomaterials Science and Engineering** has even explored hybrid approaches combining **apoptosis** and **ferroptosis**, an **iron**-dependent form of cell death, to maximize the immune-stimulating effect while delivering targeted **chemotherapy** through **nanoparticles**. ### The central role of dendritic cells The key mechanism documented in the scientific literature rests on **dendritic cells**, which pick up signals released by dying tumor cells and then migrate to the **lymph nodes** to present **tumor antigens** to T cells. This process, when it works properly, can trigger a lasting immune response, what researchers call an **antitumor memory**. It's that memory effect that legitimately excites the scientific community, since it could open the door to prolonged protection against relapse, a goal that classic **chemotherapy** cannot reach on its own. *The technical vocabulary can be off-putting, but the underlying idea is almost disarmingly simple: some cell deaths speak to the immune system, others stay mute. Learning to trigger the former rather than the latter is the whole point.* ## What recent research adds to the picture ### Therapeutic combinations under study A systematic review published in **June 2025** and indexed on **PubMed Central** identified **fourteen eligible studies**, conducted between **2010** and **2025**, exploring the induction of **immunogenic cell death** through **radiotherapy**, **chemotherapy**, **photodynamic therapy**, **oncolytic virotherapy**, or agents targeting oxidative stress and lysosomes. Most of these studies demonstrated efficacy under preclinical conditions, but two relied solely on **in vitro** data, a useful reminder that the road to the clinic remains long. This work fits into a broader trend in **immuno-oncology** research: combining **existing treatments**, rather than waiting for an isolated miracle molecule, to achieve a **synergistic effect** on otherwise resistant tumors. ### The problem of cold tumors A significant share of **solid tumors** is labeled cold by researchers, meaning poorly infiltrated by immune cells and therefore poorly responsive to **checkpoint inhibitor** therapies that have nonetheless revolutionized the treatment of certain cancers over the past decade. One of the hopes carried by **immunogenic cell death** is precisely to turn these **cold tumors** into **hot tumors**, more vulnerable to immune attack. That transformation, if confirmed in rigorous clinical trials, could widen the pool of patients able to benefit from current immune therapies, which today only work for a fraction of treated cases. *I find it reassuring that research is tackling the cold-tumor problem head-on instead of simply celebrating the successes already achieved on cancers that respond well to immunotherapy. It's in the hard cases that the real battle is fought.* ## The role of tumor metabolism in this equation ### Warburg, oxidative stress, and metabolic reprogramming A review published in **April 2025** highlights the link between the **metabolic reprogramming** of tumor cells and their capacity to trigger immunogenic death. The **Warburg effect**, that phenomenon by which **cancer cells** favor an inefficient but fast form of energy metabolism, directly influences how these cells respond to **oxidative stress** and, by extension, their tendency to die immunogenically or silently. This connection between **metabolism** and **immunity** opens the door to **combination therapies** targeting tumor metabolic pathways and cell-death mechanisms at the same time, an approach several teams are actively exploring according to that same review. ### Why this complexity shouldn't discourage the reader I understand that this **pileup of biological mechanisms** can feel dry to anyone outside the field. But there's a simple lesson to draw from it: **cancer** is not a monolithic enemy, and every tumor negotiates differently with its immune environment. Understanding these negotiations, cell by cell, pathway by pathway, is exactly what allows researchers to imagine therapeutic combinations smarter than the blind chemical carpet-bombing of past decades. It's a **battle of precision**, not a battle of brute force, and it may be the real **quiet revolution** of contemporary **oncology**. *I far prefer this slow, methodical precision medicine to the spectacular promises that almost always disappoint. Complexity isn't an obstacle to public understanding, it's an invitation to patience.* ## The limits that science itself acknowledges ### From the lab to the patient, a long road still ahead It would be dishonest of me to suggest this research is about to transform how **cancer** is treated in clinical practice. The vast majority of available data comes from **preclinical models**, meaning experiments in cell culture or in animals, whose results don't always translate reliably to humans. That's one of the reasons so many promising leads in **oncology** ultimately fail during late-phase clinical trials. The authors of the systematic reviews I consulted themselves insist on this fragmentation of the data and on the need for larger-scale **randomized clinical trials** before anything definitive can be said about the clinical efficacy of these approaches. ### The risk of media over-promising This columnist has seen enough splashy headlines about **cancer** breakthroughs that, a year later, had vanished from the radar without ever reaching the clinic. That pattern wears down public trust in scientific research and feeds a cynicism toward medical announcements that is sometimes understandable. I'd rather insist on what this line of research actually represents: an active field of study, backed by serious scientific literature, but one that has not yet delivered an approved treatment built specifically on the controlled induction of **immunogenic cell death** in routine clinical practice. *I would rather disappoint slightly along the way than feed a false hope that later blows up in the face of a patient or a family. That may be the most basic responsibility of a columnist who touches on medical matters.* ## What this means for today's patients ### No immediate change to treatment protocols Let's be clear: a patient being treated today for **cancer** will not see their protocol changed because of these findings. Current treatments, **chemotherapy**, **radiotherapy**, checkpoint-inhibitor **immunotherapies**, **surgery**, remain the validated options endorsed by regulatory agencies and oncology societies. What this research feeds is the next generation of combined protocols, the ones that could emerge in **five**, **ten**, or **fifteen years** if clinical trials confirm today's preclinical promise. ### The importance of staying close to primary sources For patients and families seeking reliable information, I always recommend favoring primary sources, peer-reviewed publications in journals like **Nature**, rather than the sometimes-distorted summaries circulating on social media. Platforms such as **EurekAlert** and weekly cancer-research digests offer direct access to institutional releases without the sensationalist filter. This rigor in choosing sources isn't an intellectual luxury, it's protection against the exploitation of vulnerable patients searching for hope. *I'll say it plainly: science communication carries an ethical responsibility toward sick people. Sowing false hope to generate clicks is a fault I refuse to commit, even if it makes my columns less spectacular.* ## The broader context of oncology research ### A decade of real progress in immunotherapy This line of research needs to be placed in a broader context: the past decade has seen **immunotherapy** transform the outlook for certain cancers once considered near-automatic death sentences, notably some **advanced melanomas** and certain **lung cancers**. **Immune checkpoint inhibitors**, targeting proteins like **PD-1** or **CTLA-4**, opened a new therapeutic era validated by multiple randomized clinical trials. **Immunogenic cell death** fits into the continuity of that revolution, seeking to extend its benefits to cancers that, so far, resist treatments that have become standards of care in several indications. ### Why the West must keep investing in this research I firmly believe that sustained funding for basic oncology research, notably within Western academic institutions and through agencies like the **National Institutes of Health** in the United States or their European counterparts, remains an essential strategic investment. This kind of foundational research, often invisible to the public, is precisely what enabled the immunotherapy breakthroughs seen over the past **fifteen years**. Cutting that funding in the name of short-term savings would amount to mortgaging tomorrow's treatments, a reality policymakers should keep in mind when weighing budget decisions. *Basic research doesn't produce spectacular results every budget cycle, and that's precisely why it's vulnerable to political cuts. I'm arguing for institutional patience toward a science that advances through small, rigorous steps.* ## Nanotechnology in service of this strategy ### Targeting cell death with precision **Nanoparticle**-based approaches, like those combining **apoptosis** and **ferroptosis** mentioned above, illustrate a deep trend in modern oncology: using nanoscale carriers to deliver therapeutic agents directly into the heart of tumor cells, while limiting collateral damage to surrounding healthy tissue. These **micelles** loaded with **doxorubicin** and coated with iron complexes, studied in specialized publications, show how materials chemistry now directly meets cancer biology to optimize both the efficacy and safety of treatments. ### A field that demands interdisciplinary collaboration This kind of innovation could not exist without close collaboration between **chemists**, **biologists**, **immunologists**, and **clinicians**, an interdisciplinary research dynamic that increasingly defines cutting-edge oncology. This organizational complexity is itself a challenge, requiring funding and collaboration structures capable of bridging disciplines that historically operated in separate silos. The institutions that manage to break down these silos, often major university cancer centers, end up in a leadership position in this global scientific race. *I marvel at seeing materials chemistry and immunology converge this way. It's a reminder that major medical advances rarely spring from a single isolated discipline, but from the sometimes uncomfortable dialogue between several fields of knowledge.* ## The economic and industrial weight of this scientific race ### Private investment following the basic science Behind the academic publications lies a very real industrial ecosystem: North American and European **biotechnology** companies are already investing in developing molecules capable of artificially inducing targeted **immunogenic cell death**, betting on the long-term commercial potential of these preclinical discoveries. This private funding, often less visible than public grants, sometimes speeds up the move from the lab bench to the first clinical trials. These investments nonetheless remain risky, since most drug candidates in **oncology** fail before ever reaching the market, a reminder that financial speculation must never replace scientific rigor in evaluating these leads. ### A battle as regulatory as it is scientific Agencies like the **Food and Drug Administration** in the United States or the **European Medicines Agency** will, in due time, have to evaluate these future therapeutic candidates against extremely strict safety and efficacy standards, a process that generally takes several years after late-phase clinical trials conclude. This regulatory rigor, though sometimes criticized for its slowness, remains an essential protection for patients against poorly evaluated treatments. It's a delicate balance between the legitimate urgency of patients waiting for new options and the caution needed to avoid repeating past mistakes with treatments approved too quickly and later pulled from the market. *I will never give in to the temptation of framing regulatory slowness as a mere bureaucratic obstacle. That slowness, however frustrating for waiting patients, has saved lives by keeping insufficiently tested treatments off the market.* ## What patients should concretely take away ### Neither miracle nor disillusion: one serious lead among others If you or someone close to you is currently going through cancer treatment, this research should neither give you false immediate hope nor be dismissed as a mere academic exercise without consequence. It represents one of many active leads that, added together, have allowed survival rates for certain cancers to improve significantly over recent decades. It's these incremental advances, rarely spectacular when taken individually, that end up collectively transforming the disease's overall long-term outlook. ### The importance of dialogue with care teams For any question about available treatment options, including participation in clinical trials exploring these new approaches, direct dialogue with the treating **oncology** team remains irreplaceable. No piece of science writing, however rigorous, can substitute for an individualized clinical evaluation. It's an obvious point worth repeating, given how strong the temptation of internet **self-diagnosis** can be when facing a disease as frightening as **cancer**. *I'll close this section by insisting on a simple point: my role is to inform, never to replace medical advice. That's a boundary I set willingly and without complexes.* ## A global scientific race, with quiet geopolitical stakes ### The silent competition among major research centers Behind this seemingly purely biomedical research lies a very real international scientific competition, among major **North American**, **European**, and **Asian** research centers, to patent and commercialize the most promising therapeutic innovations in oncology. This economic and strategic dimension is never entirely absent from labs, even the most academic ones. Western countries, with their long-established research infrastructure and relatively stable regulatory frameworks, retain a significant edge in this race, an edge worth preserving through steady and predictable public funding. ### Why this competition ultimately benefits patients Far from being a mere contest of national prestige, this international scientific competition paradoxically speeds up the spread of knowledge, as each team seeks to publish its results quickly in peer-reviewed journals accessible worldwide, a dynamic that ultimately benefits patients everywhere, regardless of nationality. It's one of the healthiest **paradoxes** of modern scientific research: **institutional rivalry** feeds, rather than hinders, the flow of medical knowledge across the planet. *I see in this international scientific competition a form of virtuous rivalry, as long as it stays anchored in open publication of results rather than in the strategic hoarding of information.* ## The questions still unanswered ### What will the optimal therapeutic window be One of the questions current literature has not resolved concerns the precise timing and exact dose needed to trigger truly immunogenic cell death without causing disproportionate side effects on surrounding healthy tissue. This **therapeutic window**, narrow by nature, still needs to be precisely mapped for each cancer type and each therapeutic combination under consideration. It's a job of **meticulous calibration** that will require several more years of **preclinical trials** before reaching the maturity needed for large-scale **clinical trials** in humans. ### Individual variability among patients Another major unknown concerns the variability of the **immune system** from one patient to another, which could explain why some respond favorably to a therapy inducing immunogenic cell death while others show no measurable improvement. This biological heterogeneity considerably complicates the design of standardized clinical trials. Researchers are currently exploring **predictive biomarkers** that could eventually help identify the patients most likely to benefit from these approaches, an approach characteristic of contemporary **precision medicine**. *I find this scientific uncertainty reassuring rather than worrying: it proves researchers aren't making claims broader than what the data can actually support.* ## What this research changes for the next generation of researchers ### Training a new generation able to navigate this complexity **Immunogenic cell death** shows just how much the training of future **oncology researchers** must now integrate cross-cutting skills, spanning molecular biology, immunology, materials chemistry, and bioinformatics. Young scientists entering this field today must learn to navigate several disciplines at once, a far heavier demand than what was placed on previous generations of researchers specialized in a single narrow field. Western universities that invest in genuinely interdisciplinary doctoral programs, rather than siloed tracks, gain a real competitive edge in attracting the world's best talent to this **cancer** research. ### Open data access as a collective accelerator Another decisive factor for the future of this research lies in the availability of open data shared between labs, rather than the competitive hoarding of raw results. Public registries like **ClinicalTrials.gov** and genomic databases accessible to researchers worldwide considerably speed up the pace of discovery by letting each team build on others' results instead of repeating the same experiments in isolation. This culture of sharing, still uneven across countries and institutions, remains an underused lever for accelerating the path of **immunogenic cell death** from the lab toward concrete clinical applications for patients. *I believe the next great advance against cancer will come as much from better global scientific collaboration as from an isolated miracle molecule. Investing in training and data sharing is just as strategic as investing in a single star laboratory.* ## What this research reveals about our collective relationship with cancer ### Moving past simplistic war vocabulary The usual vocabulary around **cancer**, the language of combat, of war, of struggle, deserves to be tempered by a finer understanding of the biological mechanisms at play. **Immunogenic cell death** shows that the fight against cancer is not simply a binary opposition between aggressive treatment and resistant tumor, but a complex negotiation between molecular signals, immune cells, and the tumor environment. This nuance, far from being a semantic detail, directly shapes how **patients** and families psychologically experience their care journey, a **human dimension** that science communication should never overlook. ### Measured hope as an ethical stance I'll close this reflection by owning a stance I believe is right: speaking of hope without promising a miracle, informing without dramatizing, simplifying without betraying the real complexity of the available scientific data. It's a constant balancing act, but it's the one I strive to maintain every time I take on a subject as sensitive as **cancer**. Patients and their loved ones deserve honest information, neither catastrophizing nor euphoric, and that's the editorial line I will keep defending in my future columns on these medical questions. *I believe measured hope is the only form of hope truly respectful toward people going through cancer. Everything else is marketing dressed up as science.* ## Conclusion: a lead that deserves patient follow-up rather than hype ### Summarizing without betraying the complexity **Immunogenic cell death**, with its variants **immunogenic apoptosis**, **necroptosis**, and **pyroptosis**, represents an active and serious line of research for strengthening the immune system's attack on cancerous tumors. It replaces no existing treatment and guarantees no cure, but it enriches the scientific understanding of mechanisms that could, in time, improve the efficacy of immunotherapies already in clinical use. This distinction between promising research and available treatment must stay at the center of any **public communication** on this subject, to avoid both **unjustified despair** and **disproportionate hope** among affected patients. ### Watching for the next scientific publications I will keep following this line of research in future columns, as new publications, ideally drawn from clinical trials rather than only preclinical models, come to enrich or nuance what we know today. That's the natural rhythm of science, slow, methodical, sometimes frustrating for those hoping for immediate answers, but it's the only rhythm that guarantees the reliability of the conclusions drawn from it. Until then, caution and patience remain the best allies of anyone closely following advances in the fight against **cancer**. *If I had to sum up this column in one sentence, it would be this: cancer science advances through the fine-grained understanding of invisible mechanisms, not through spectacular announcements. That's less marketable, but it's the truth I choose to defend.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - Immunogenic cell death in cancer immunotherapy — PubMed, BMB Reports, mai 2023 - Immunogenic Cell Death as a Target for Combination Cancer Therapy — PubMed Central, juin 2025 - Immunogenic Cell Death and Metabolic Reprogramming in Cancer — PubMed, avril 2025 ### Secondary sources - Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors — Nature, décembre 2024 - Immunogenic cell death in cancer therapy: present and emerging concepts — PubMed Central - Enhanced Immunogenic Cell Death by Apoptosis/Ferroptosis Hybrid Nanoparticles — ACS Biomaterials Science and Engineering, novembre 2022 - Immunotherapies inducing immunogenic cell death in cancer — Frontiers in Immunology, novembre 2023 --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/quand-la-mort-d-une-cellule-cancereuse-devient-une-arme-immunitaire